PriceTargets.com logo

Fresh Tracks Therapeutics - FRTX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.74 As of 12/20/2024 06:18 PM ET
▼ -0.0025 (-0.34%)

This chart shows the closing price for FRTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fresh Tracks Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FRTX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Fresh Tracks Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.74.

This chart shows the closing price for FRTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Fresh Tracks Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/16/2022OppenheimerLower Target$4.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

  • No positive mentions tracked during this time.

Very Positive

Fresh Tracks Therapeutics logo
Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
Read More

Today's Range

Now: $0.74
Low: $0.74
High: $0.74

50 Day Range

MA: $0.73
Low: $0.71
High: $0.75

52 Week Range

Now: $0.74
Low: $0.55
High: $1.03

Volume

839 shs

Average Volume

12,764 shs

Market Capitalization

$4.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.5

Frequently Asked Questions

What sell-side analysts currently cover shares of Fresh Tracks Therapeutics?

The following equities research analysts have issued reports on Fresh Tracks Therapeutics in the last twelve months:
View the latest analyst ratings for FRTX.

What is the current price target for Fresh Tracks Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Fresh Tracks Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Fresh Tracks Therapeutics in the next year.
View the latest price targets for FRTX.

What is the current consensus analyst rating for Fresh Tracks Therapeutics?

Fresh Tracks Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FRTX.

What other companies compete with Fresh Tracks Therapeutics?

Other companies that are similar to Fresh Tracks Therapeutics include Aprea Therapeutics, MEI Pharma, Synlogic, BioXcel Therapeutics and BioLineRx. Learn More about companies similar to Fresh Tracks Therapeutics.

How do I contact Fresh Tracks Therapeutics' investor relations team?

Fresh Tracks Therapeutics' physical mailing address is 5777 Central Ave Ste 102, Boulder, Colorado 80301-2870. The company's listed phone number is (720) 505-4755 and its investor relations email address is [email protected]. The official website for Fresh Tracks Therapeutics is brickellbio.com. Learn More about contacing Fresh Tracks Therapeutics investor relations.